3D
Molecular Sciences Presents its New Patented 3D Encoded
Particle Array Tool for Multiplexing Bioassays at BioArray Europe
1
October 2002, Cambridge, UK…
3D Molecular Sciences presented a poster providing new assay data on the
Company’s multiplexing enabling platform technology for molecular
medicine at the BioArray Europe conference, taking place in Cambridge, UK,
on 1 October 2002. The new patented assay system consists of
microfabricated encoded particles of a variety of designs, attachment
chemistries and a choice of readers to interpret the results.
The
poster presentation, entitled Several
Assay Systems Presented Using a New Patented 3D Encoded Particle Array
Tool for Multiplexing Bioassays, shows new data demonstrating the
compatibility of the Company’s individually coded particles with a
diverse range of assays including nucleic acids and cytokines. The
Company’s technology platform offers an inexpensive and flexible tool to
the pharmaceutical, biotech and clinical diagnostic industries that allows
for a superior volume of tests, a scaleable capability and multiplexing of
samples. It has the potential to screen for gene-linked diseases such as
cancer, Alzheimer's, obesity and cystic fibrosis. It can also offer great
possibilities in compound library screening, environmental monitoring and
in anti-terrorism systems.
Dr
Elizabeth Hill, 3D Molecular Sciences’ CEO, said, “Our 3DMS™ 3D
particle array tools are designed to carry out large-scale bioassay
analysis required in drug discovery, drug development and in diagnostics
in a low cost and fast manner. Our data presented at this conference
clearly illustrates the capability this platform has, and we will continue
to maintain our technology programme so we can exploit this platform to
the full.”
The
Company’s 3DMS™ particle array system is a new, patented assay and
detection technology that uses individually microscopic encoded particles
for the detection of biological content or biochemical interactions in a
wide variety of analytical bioassays and test formats. Such formats are
for proteomics, immunoassays gene expression and SNP analysis.
Work
is currently underway on a number of further commercial assay systems to
illustrate the 3DMS 3D-particle array capability. The Company has a strong
patent position and welcomes the opportunity to discuss licensing and
collaboration with commercial partners to build and develop this platform
further with suitable commercial assay applications.
Ends
Notes
for editors:
1.
3D MOLECULAR SCIENCES LTD was
incorporated in October 2001 as a spin out from the Generics Group to
commercialise a particle-based assay platform designed for large scale
genomic and proteomic analysis, as well as diagnostic and combinatorial
chemistry. The company operates from premises at Harston, Cambridgeshire,
UK. The company has secured funding of £0.5m ($0.7m) from both the
generics group and the InterIkea Fund, a fund managed by Generics Asset
Management Ltd.
For
more information, visit www.3d-molecularsciences.com
2.
THE GENERICS GROUP (GENERICS)
is a leading integrated technology consulting, development and investment
organisation, with an international reputation for successfully
commercialising emerging science and technology.
Generics
invests in and develops technologies that underpin the future of the
widest range of industries. Its key areas of expertise include:
engineering, materials, telecommunications, life sciences, business
innovation and electronics.
Generics’
facilities include state-of-the-art laboratories and are located in
Cambridge, UK; in Zurich, Switzerland; in Stockholm, Sweden; and in Boston
and Baltimore in the USA. Generics has over 300 employees, of which more
than half are high-calibre technology professionals.
